ENSC
Ensysce Biosciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.46
+3.57%Year over year
Reported trailing growth
- Revenue
- -80.7%
- EBITDA
- —
- EBIT
- -90.4%
- EPS
- +32.4%
- Free cash flow
- -44.9%
- Operating cash flow
- -42.9%
Forward estimates
Based on analyst estimates
- Revenue
- +106.1%
- EBITDA
- +61.9%
- EPS
- +86.6%
Three-year CAGR
- Revenue
- —
- EBITDA
- -51.6%
- EBIT
- -52.2%
- Net income
- -27.4%
- EPS
- +12.9%
- Free cash flow
- -5.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026